TNFSF11 and osteoporosis: Another clinical study demonstrated that glycemic control improved in prediabetic and T2DM patients with osteoporosis who were treated with the RANKL-specific antibody denosumab, compared with those treated with bisphosphonates or calcium plus vitamin D, and the effect persisted after adjusting for BMI [36].